Biopharmaceutical firm Urovant Sciences announced that it has acquired global rights for the development and commercialisation of hp - K , a novel investigational gene therapy for the treatment of overactive bladder ( OAB ) . The company will study the efficacy of hMaxi - K as a treatment for patients with OAB symptoms for whom oral pharmacologic therapy has not been successful . It expects to launch the Phase clinical hMaxi - K study next year .
Biopharmaceutical firm Urovant Sciences announced that it has licensed global rights for the development and commercialisation of hMaxi-K, a novel investigational gene therapy for the treatment of overactive bladder (OAB). The company will study the potential of hMaxi-K as a treatment for patients with OAB symptoms for whom oral pharmacologic therapy has not been successful. It expects to initiate the Phase 2 hMaxi-K study next year.